Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AV 101

Next Previous
Search
Drug Profile

AV 101

Alternative Names: 4-Chlorokynurenine - VistaGen; 4-CL-KYN; 7-CL-KYNA; AV-101; L-4-chlorokynurenine; L-4-CL-KYN

Latest Information Update: 07 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Artemis Neuroscience
  • Developer Baylor College of Medicine; Jade Biosciences; National Institute of Mental Health; VistaGen Therapeutics
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antihypertensives; Antiparkinsonians; Behavioural disorder therapies; Butyric acids; Neuroprotectants; Small molecules
  • Mechanism of Action Kynurenine modulators; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Hypertension
  • Phase II Major depressive disorder
  • Phase I Neurological disorders; Neuropathic pain
  • No development reported Epilepsy; Huntington's disease; Parkinson's disease; Psychiatric disorders; Suicidal ideation

Most Recent Events

  • 28 Apr 2025 Aerovate Therapeutics has merged with Jade Biosciences to form Jade Biosciences
  • 05 Feb 2025 Vistagen Therapeutics has patent protection for use of AV 101 for the treatment of Neuropathic pain in USA
  • 27 Dec 2023 Phase I development is ongoing in Neuropathic pain (healthy volunteers) in USA (Vistagen pipeline, December 2023)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top